For the Inventor, By the Inventor

Enter assignee name

Sunnyvale, CA, United States of America

Nuvelo, Inc.

USPTO Granted Patents = 39

% Expired Patents = 76.9

Forward Citations = 469

Loading Chart...

Loading Chart...

69 inventors (with patents filed for the assignee):

Radoje Drmanac (13 out of 134 patents)

Y Tom Tang (13 out of 92 patents)

Brian Paul Chadwick (8 out of 9 patents)

4. Anna-Maria Frischauf (8 out of 9 patents)

5. George Yeung (7 out of 25 patents)

6. Chenghua Liu (7 out of 17 patents)

7. Bryan J Boyle (6 out of 10 patents)

8. Vincent P Stanton, Jr (5 out of 30 patents)

9. Nancy K Mize (5 out of 11 patents)

10. John E Ford (5 out of 18 patents)

11. Ryle W Goodrich (5 out of 5 patents)

12. Vinod Asundi (4 out of 5 patents)

13. Matthew C Arterburn (4 out of 6 patents)

14. Jian-Rui Wang (3 out of 4 patents)

15. Ivan Labat (3 out of 7 patents)

Core Competencies:

Antibodies

Stem Cell Factors

Genetic Analysis

Polypeptides

Nucleic Acids

Cancer Detection

Therapeutic Methods

Gene Expression

Chemokine Receptors

RNA Targeting

Prognosis

Disease Treatment

39 patents: Sort by Forward Citations

1. 8993726 - Antibodies to NTB-A (2015-03-31),

2. 7659054 - Methods for genetic analysis of DNA to detect sequence variances (2010-02-09),

3. 7439327 - Stem cell factor-like proteins and uses thereof (2008-10-21),

4. 7425610 - Methods and materials relating to CD84-like polypeptides and polynucleotides (2008-09-16),

5. 7411052 - Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides (2008-08-12),

6. 7320880 - Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and DNA coding for the same (2008-01-22),

7. 7319141 - Stem cell growth factor-like polypeptides (2008-01-15),

8. 7122373 - Human genes and gene expression products V (2006-10-17),

9. 7109030 - Methods of therapy and diagnosis using insulin-like growth factor binding protein-like polypeptides and polynucleotides (2006-09-19),

10. 7067301 - Methods and materials relating to novel prothrombinase-like polypeptides and polynucleotides (2006-06-27),

11. 7029677 - Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells (2006-04-18),

12. 7001731 - Chemokine receptor obtained from a cDNA library of fetal liver-spleen (2006-02-21),

13. 6979548 - Chemokine receptor obtained from a CDNA library of fetal liver-spleen (2005-12-27),

14. 6964868 - Human genes and gene expression products II (2005-11-15),

15. 6919193 - Nucleic acids and polypeptides (2005-07-19),

Company Overview

Nuvelo, Inc. is a biotechnology company based in Sunnyvale, California, specializing in the development of innovative therapeutic solutions. The organization focuses on advancing treatments primarily in the fields of hematology and oncology, leveraging cutting-edge research to address unmet medical needs. With a commitment to scientific excellence, Nuvelo aims to enhance patient outcomes through its proprietary technologies and drug development programs, contributing to the evolving landscape of biopharmaceuticals.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

39 Patents

#118 in Sunnyvale, CA

#2,092 in California

#8,823 in US

#17,448 in the World

Sunnyvale, CA, United States of America

Nuvelo, Inc.

Forward Citations = 469

69 inventors:

Radoje Drmanac (13 out of 134 patents)

Y Tom Tang (13 out of 92 patents)

Brian Paul Chadwick (8 out of 9 patents)

4. Anna-Maria Frischauf (8 out of 9 patents)

5. George Yeung (7 out of 25 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nuvelo, Inc.. Retrieved from https://idiyas.com/company/nuvelo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…